Phase 1 Study of JNJ-95566692 Alone and with JNJ-87801493 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoid Malignancies

What this Trial Is About

Researchers are evaluating the safety and clinical activity of a new drug called JNJ-95566692 alone and in combination with another drug, JNJ-87801493, for treating adults with B-cell non-Hodgkin lymphoid malignancies who have relapsed or refractory disease. This Phase 1 study aims to find the best doses and schedules for these treatments and to further assess their effects in patients who have already tried other therapies. Participants will receive escalating doses of JNJ-95566692 alone or with JNJ-87801493 during the first part of the study to determine optimal dosing. In the second part, participants will receive these drugs at the recommended doses to better understand safety, how the body processes the drugs, and their clinical impact. Both drugs are given as injections under the skin. Throughout the study, participants will be closely monitored for side effects and treatment responses over about two years and eight months. Assessments include measuring drug levels in the blood, monitoring immune responses, and evaluating disease status. Safety and effectiveness data will be collected regularly to help guide further development of these treatments.

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies